Randomised trials of endovascular therapy for distal and medium vessel occlusions have been neutral, with numerically more intracranial haemorrhage than best medical therapy, and guidelines now recommend against routine thrombectomy in this group. This narrative synthesis argues that the neutral result is partly an artefact of how the question was asked.
The case rests on heterogeneity. Distal and medium vessel occlusions vary in vessel calibre, perfusion territory, collateral dependence and access route, and the trials enrolled broadly defined populations across all of that. The authors also point to the outcome scales: presentations are often mild to moderate on severity scores that were designed around proximal occlusion, while registry data show many of these patients remain disabled on best medical therapy. Their reading is that the trials tested a device strategy borrowed from proximal thrombectomy in a population selected by a definition that groups unlike things together.
What this does not do is reopen routine thrombectomy for these patients. It argues for treating the syndrome as distinct — with its own selection features, distal-specific devices, intra-arterial thrombolysis and hybrid approaches, and outcome measures sensitive to the deficits these occlusions actually cause. For now the clinical position is unchanged, and the value of reading it is in how you document the ones you decline: record the occlusion site, the collateral status and the deficit, because that is the data a better-selected trial will need.
- Continue to follow current guidance against routine endovascular therapy for distal occlusions
- Record occlusion site, calibre, collateral status and thrombus features when you decline intervention
- Note that a low severity score does not predict a good outcome in this group
- Follow these patients up — registry data show substantial residual disability on medical therapy alone
- Treat emerging distal-specific techniques as trial territory, not established practice
Why it matters
It explains why a biologically plausible intervention failed, in a way that changes what the next trial should enrol rather than what you do today.
Don't overread it
This is an interpretative narrative review, not new trial data — nothing here overturns the guideline recommendations it discusses.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for neurology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free